Midgard Science

Halozyme

Boston, MA, United States elektrofi.com

From their website, Nov 2026

Work here? Claim this listing

About

Halozyme’s Elektrofi unit develops formulation technology for biologic therapies, focusing on low-volume, stable, hyper-concentrated subcutaneous delivery. It works with biopharmaceutical partners on protein therapeutics and related drug-product formats.

Services

  • Biologic formulation development

    Develops low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery.

  • Subcutaneous delivery enablement

    Supports conversion of biologic therapies from intravenous administration to subcutaneous administration.

  • Asset-specific formulation customization

    Creates molecule- and asset-specific formulations for nearly any protein therapeutic.

  • Delivery-format compatibility support

    Develops formulations compatible with vials, pre-filled syringes, cartridges, and auto-injectors.

  • Formulation technology development

    Develops hyper concentrated microparticle formulations for biologic therapies.

  • Partnered drug development

    Collaborates with biopharmaceutical companies on development programs for biologic therapies.

  • Commercial-scale GMP manufacturing capacity development

    States plans to establish Ph3 and commercial-scale GMP manufacturing capacity.

Turnaround
Done in seconds, not hours

Capabilities

Scale and capacity
Up to 500 mg/ml · Ph3 and commercial-scale GMP manufacturing capacity · Ph3 manufacturing capacity · Commercial-scale GMP manufacturing lines

Modalities and species

Modalities
Antibody · Cell therapy

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    Scope: manufacturing capacity

Industries served

  • Biotech

Locations

Based in
Boston, MA, United States
Sites
Boston, United States
Serves
global

Public records

Parent company
HALOZYME THERAPEUTICS, INC. · US GLEIF

Similar labs

Work here? Claim this listing